These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 26897754)
1. Tissue penetration and exposure of cefepime in patients with diabetic foot infections. So W; Kuti JL; Shepard A; Nugent J; Nicolau DP Int J Antimicrob Agents; 2016 Mar; 47(3):247-8. PubMed ID: 26897754 [No Abstract] [Full Text] [Related]
2. Pseudomonas aeruginosa infections in the podiatric patient. Le Frock JL; Ristuccia AM Clin Podiatr Med Surg; 1990 Jul; 7(3):493-500. PubMed ID: 2119248 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of anti-pseudomonal antibiotics: need to reconsider the empirical use of cefepime. Kotwal A; Biswas D; Kakati B; Thakuria B; Bhardwaj N Indian J Med Res; 2014 Oct; 140(4):560-2. PubMed ID: 25488453 [No Abstract] [Full Text] [Related]
4. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925 [TBL] [Abstract][Full Text] [Related]
5. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study. Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874 [TBL] [Abstract][Full Text] [Related]
7. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. Deal EN; Micek ST; Reichley RM; Ritchie DJ Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902 [TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa. Gelfand MS; Cleveland KO Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991 [No Abstract] [Full Text] [Related]
9. [Antibiotic resistance of some Pseudomonas aeruginosa isolates]. Matinca D; Vancea D; Boboş C; Serban O Bacteriol Virusol Parazitol Epidemiol; 2003; 48(2-3):157-61. PubMed ID: 15341333 [No Abstract] [Full Text] [Related]
10. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356 [TBL] [Abstract][Full Text] [Related]
11. [Cefoperazone in infections caused by resistant agents, with special reference to Pseudomonas aeruginosa]. Torres A; Vega J; Aguirre M; Alés JM Rev Clin Esp; 1982 Feb; 164(4):229-32. PubMed ID: 6211752 [No Abstract] [Full Text] [Related]
12. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff DA; Nicolau DP Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574 [TBL] [Abstract][Full Text] [Related]
13. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. Vahaboglu H; Saribaş S; Akbal H; Ozturk R; Yucel A J Antimicrob Chemother; 1998 Aug; 42(2):269-70. PubMed ID: 9738851 [No Abstract] [Full Text] [Related]
14. Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia. Kim J; Kang CI; Baek JY; Cho SY; Kim SH; Ko KS; Chung DR; Peck KR; Song JH Int J Antimicrob Agents; 2014 Apr; 43(4):391-3. PubMed ID: 24637223 [No Abstract] [Full Text] [Related]
15. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Roos JF; Bulitta J; Lipman J; Kirkpatrick CM J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209 [TBL] [Abstract][Full Text] [Related]
18. [Clinical studies on cefsulodin in the field of pediatrics]. Yanagisawa K; Yanagisawa K; Hoshina H; Ichihashi H Jpn J Antibiot; 1982 Nov; 35(11):2683-7. PubMed ID: 6820393 [TBL] [Abstract][Full Text] [Related]
19. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741 [TBL] [Abstract][Full Text] [Related]